Breast Cancer Trial

Neuropathy in Black Women

Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients with Stage I-III Breast Cancer

 

Nerve damage, known as neuropathy, is a painful side effect of chemotherapy. Trial EAZ171 is studying neuropathy in Black women with breast cancer. For more information, visit the EAZ171 Home Page.

Physician and Research Staff Educational Material

This material is intended for promotional use among health care professionals and is NOT intended for use as patient educational material.

    • Physician Fact Sheet: schema, study objectives, eligibility criteria, and other key information about the study

Patient Educational Material

Participating sites should note that the Central Institutional Review Board (CIRB) has approved this material. For sites utilizing local IRBs, please submit this in accordance with your local IRB policies prior to use.

    • Study Summary for Patients: Study rationale/objectives, details regarding treatment, and a simplified schema in lay language to provide a more visual description of the trial to patients

Information and Assistance from the National Cancer Institute

    • Locations and other information
    • Trained information specialists at the NCI are available to answer cancer-related questions from patients, family members or friends, health care providers, and researchers. Visit the NCI’s Cancer Information Service webpage for contact instructions, including telephone, live chat, email, and mail.

ClinicalTrials.gov ID: NCT04001829

Return to Home Page | Return to EAZ171 Home Page | Review Other Active Trials